Cargando…

Recent Concepts of Ovarian Carcinogenesis: Type I and Type II

Type I ovarian tumors, where precursor lesions in the ovary have clearly been described, include endometrioid, clear cell, mucinous, low grade serous, and transitional cell carcinomas, while type II tumors, where such lesions have not been described clearly and tumors may develop de novo from the tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koshiyama, Masafumi, Matsumura, Noriomi, Konishi, Ikuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017729/ https://www.ncbi.nlm.nih.gov/pubmed/24868556 http://dx.doi.org/10.1155/2014/934261

Ejemplares similares

Subtypes of Ovarian Cancer and Ovarian Cancer Screening
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Clinical Efficacy of Ovarian Cancer Screening
por: Koshiyama, Masafumi, et al.
Publicado: (2016)

The effect of the type of dietary protein on the development of ovarian cancer
por: Taha, Ahmed A.A., et al.
Publicado: (2018)

Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2016)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
por: Horikawa, Naoki, et al.
Publicado: (2020)

Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction
por: Mandai, Masaki, et al.
Publicado: (2015)

Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix
por: Nagura, Michikazu, et al.
Publicado: (2014)

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
por: Horikawa, Naoki, et al.
Publicado: (2015)

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Epigenetic and genetic dispositions of ovarian carcinomas
por: Yamaguchi, Ken, et al.
Publicado: (2014)

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma
por: Abou-Taleb, Hisham, et al.
Publicado: (2016)

ASGO 2nd International Workshop on Gynecologic Oncology
por: Matsumura, Noriomi, et al.
Publicado: (2013)

Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer
por: Sakae, Chieko, et al.
Publicado: (2016)

Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
por: Konishi, Ikuo, et al.
Publicado: (2022)

Scientific evaluation of alleged findings in HPV vaccines: Molecular mimicry and mouse models of vaccine‐induced disease
por: Matsumura, Noriomi, et al.
Publicado: (2022)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
por: Nakai, Hidekatsu, et al.
Publicado: (2022)

Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine–induced adverse events
por: Matsumura, Noriomi, et al.
Publicado: (2023)

Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival
por: Amano, Yasuaki, et al.
Publicado: (2015)

Histotype-specific copy-number alterations in ovarian cancer
por: Huang, Ruby YunJu, et al.
Publicado: (2012)

Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2019)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Murakami, Ryusuke, et al.
Publicado: (2021)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report
por: AMANO, YASUAKI, et al.
Publicado: (2013)

Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes
por: Kitamura, Sachiko, et al.
Publicado: (2017)

Recent insights into the role of NF-kappaB in ovarian carcinogenesis
por: Alvero, Ayesha B
Publicado: (2010)

Recent Topics in Chemical Carcinogenesis
por: Craig, A. W.
Publicado: (1977)

Antiproliferative Properties of Type I and Type II Interferon
por: Bekisz, Joseph, et al.
Publicado: (2010)

Mucin-Type O-Glycosylation in Gastric Carcinogenesis
por: Duarte, Henrique O., et al.
Publicado: (2016)

Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation
por: Taki, Mana, et al.
Publicado: (2018)

Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy
por: Murakami, Kosuke, et al.
Publicado: (2020)

The Effects of the Dietary and Nutrient Intake on Gynecologic Cancers
por: Koshiyama, Masafumi
Publicado: (2019)

Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma
por: Hayashi, Takuma, et al.
Publicado: (2023)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Conservative Management for Retained Products of Conception in Late Pregnancy
por: Fujishima, Risa, et al.
Publicado: (2023)

Lesser-Known Molecules in Ovarian Carcinogenesis
por: Lozneanu, Ludmila, et al.
Publicado: (2015)

Origin of the blueshift of photoluminescence in a type-II heterostructure
por: Jo, Masafumi, et al.
Publicado: (2012)

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors
por: Beeghly-Fadiel, Alicia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5trt3b699c1311fjdq34cf4urm